NCT06635330View on ClinicalTrials.gov

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

September 22, 2026

Study Completion Date

September 22, 2027

Conditions
Relapse/Refractory B-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

anti-CD19 CAR T cell therapy

Anti-CD19 CAR-T cell therapy for R/R B-ALL pediatric patients. For patients 50 kg and less: 0.2 to 5 in ten to the power of six live CAR+ T cells per kilogram of body weight/ For patients over 50 kg: 0.1 to 2.5 in ten to the power of eight live CAR+ T cells (without considering weight).

Trial Locations (1)

1419733151

RECRUITING

Pediatric cell and gene therapy research center, Children medical center, Tehran

All Listed Sponsors
lead

Kara Yakhteh Tajhiz Azma Company

NETWORK

NCT06635330 - Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL | Biotech Hunter | Biotech Hunter